Lantheus Medical Imaging, Inc.
331 Treble Cove Road
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.
Mary Anne Heino
President and Chief Executive Officer
Chief Financial Officer and Treasurer
Senior Vice President, Technical Operations
Senior Vice President - Law and Public Policy, General Counsel and Secretary
Sarah Le Roy
Senior Vice President, Human Resources
Senior Vice President, Corporate Development
Cesare Orlandi, M.D.
Chief Medical Officer
Senior Vice President, Research and Pharmaceutical Development
Senior Vice President, Quality
113 articles with Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging Presents Preliminary Data on Novel PET Myocardial Perfusion Imaging Agent Protocol at SNM Annual Meeting
Lantheus Medical Imaging Presents Phase 1 Data Highlighting Safety, Dosimetry and Tolerability of Novel PET Heart Failure Imaging Agent at SNM Annual Meeting
Lantheus Medical Imaging Presents Preliminary Data Comparing Novel Cardiac PET Imaging Agent With SPECT at SNM Annual Meeting
Lantheus Medical Imaging, Inc. Announces Magnetic Resonance Angiography (MRA) Contract Award for ABLAVAR(R) With Amerinet, Inc.
Lantheus Medical Imaging Announces Increased Access to Medical Isotope Molybdenum-99 From Czech Nuclear Research Institute
Lantheus Medical Imaging to Present Data on Cardiovascular PET Imaging Pipeline Candidates at SNM Annual Meeting
Lantheus Medical Imaging Announces Appointment of Dana S. Washburn, M.D., as Vice President, Clinical Development and Medical Affairs
Lantheus Medical Imaging Presents Preliminary Phase 2 Data With Flurpiridaz F 18 (BMS747158), a Novel PET Cardiac Imaging Agent, at the American College of Cardiology 59th Annual Scientific Session
Lantheus Medical Imaging to Present New Data on Novel PET Cardiac and Heart Failure Imaging Agents at the American College of Cardiology 59th Annual Scientific Session in Atlanta
Lantheus Medical Imaging Announces Appointment of Robert A. Spurr as Vice President, Sales and Marketing
Lantheus Medical Imaging Launches ABLAVAR(TM) (Gadofosveset Trisodium), a New Diagnostic Magnetic Resonance Angiography Agent
Lantheus Medical Imaging: Data Featuring Gadofosveset Trisodium, the First and Only MRA Blood Pool Agent Approved in The U.S., Presented At MRA-Club 09: The 21st Annual International Conference on Magnetic Resonance Angiography
Lantheus Medical Imaging Announces FDA And Health Canada Approval Of Australian Nuclear Science And Technology Organisation (Ansto)-Supplied Key Medical Isotope To Manufacture Technelite(R) Generator
Scientists Who Made Significant Contribution to Discovery of Lantheus Medical Imaging's Cardiolite(R) Honored with Prestigious Nuclear Medicine Award at SNM Annual Meeting
Lantheus Medical Imaging: BARI 2D Study Presented at American Diabetes Association Scientific Sessions Underscores Utility of SPECT Myocardial Perfusion Imaging in Identifying Cardiovascular Risk and Evaluating Treatment Outcomes for Patients with Type 2
Lantheus Medical Imaging: SPECT MPI with Cardiolite(R) Used in BARI 2D Study to Evaluate Type 2 Diabetes and Coronary Artery Disease Treatment Strategies
Lantheus Medical Imaging Completes Enrollment Of CaRES Registry to Further Evaluate DEFINITY(R) in Patients with Suboptimal Echocardiograms
Lantheus Medical Imaging Takes Proactive Steps to Mitigate Impact of Global Molybdenum-99 Supply Crisis on Operations